Group 1 - Tsugami Machine Tool China (01651) saw a rise of over 5.4% due to increased demand for high-precision machine tools in emerging sectors like new energy vehicles and artificial intelligence as China's economy gradually recovers [1] - Black Sesame Intelligence (02533) increased by over 2.2% after announcing that its flagship product, the Huashan A1000 automotive-grade high-performance driving assistance chip, has been successfully integrated into Desay SV's new low-speed unmanned vehicle brand "Chuanxing Zhiyuan" S6 series [1] - Zai Xin Bio-B (02509) rose over 5.8% after receiving clinical trial approval for its self-developed long-acting dual antibody QX027N injection, intended for the treatment of asthma and atopic dermatitis [1] - CanSino Biologics (06185) increased nearly 5% as it announced the initiation of Phase I clinical trials for its inhaled tuberculosis vaccine in Indonesia [1] Group 2 - Kingsray Biotechnology (01548) rebounded over 4.48% following the financial performance disclosure of its joint venture Legend Biotech for the third quarter ending September 30, 2025 [2] - Fuhong Hanlin (02696) rose over 5.2% after its PD-1 antibody drug, Surufilumab injection, was proposed for breakthrough therapy designation for use in combination with chemotherapy for gastric cancer [2] - Yidu International Holdings (00259) increased over 6% amid uncertainty regarding the impact of an undisclosed event on its financial statements for the year ending March 31, 2025 [2] Group 3 - Reshaping Energy (02570) surged nearly 60%, with a rise of 55.03%, following announcements from the National Energy Administration encouraging the use of green hydrogen in coal chemical projects and plans to promote over 2,000 hydrogen vehicles in Shandong Province [3] - Laika Pharmaceuticals-B (02105) saw a reverse increase of over 10.3% after granting Qilu Pharmaceutical exclusive rights for research, development, and commercialization of the breast cancer candidate drug LAE002 (afuresertib) in China [3] Group 4 - WMCH GLOBAL (08208) resumed trading with a rise of over 50%, increasing by 57.45% after announcing the sale of approximately 384 million shares, representing about 53.297% of its issued share capital [4] Group 5 - U.S. stock market opened lower, with the Nasdaq dropping 2.04%, as major tech stocks like Nvidia, AMD, and Tesla saw declines [5] - Tencent reached an agreement with Apple regarding payment processing for WeChat mini-games, potentially opening new revenue streams for Apple [5] - Mangoceuticals (MGRX.US) plummeted 32.39% after announcing partnerships with Eli Lilly and Novo Nordisk to provide users with weight loss medications [6] - Fannie Mae (FNMA.US) fell 9.82%, with a two-day cumulative drop of 20%, amid investigations into the actions of the Federal Housing Finance Agency director [6] - Disney (DIS.US) dropped 7.75% despite strong performance in streaming and theme parks, as upcoming major film releases are expected to impact first-quarter performance [6]

智通财经APP获悉，复宏汉霖(02696)再涨超5%，截至发稿，涨6.02%，报68.7港元，成交额3425.31万港 元。 值得注意的是，11月6日与11月10日，博裕资本(Boyu Capital Investment Management Limited)分别买入复 宏汉霖262,500股及80,000股H股，两次增持后其H股好仓比例由5.84%跃升至7%。据悉，今年6月18日， 博裕资本就已斥资2126.73万港元增持，将好仓比例从4.89%提升至5.15%，跨越5%的举牌线。 消息面上，11月12日，CDE官网公示，复宏汉霖PD-1抗体药物斯鲁利单抗注射液（H药）拟纳入突破性 疗法，用于联合化疗新辅助/辅助治疗胃癌，这是其首次拟获此认定。据悉，H药是全球首个获批一线治 疗小细胞肺癌的抗PD-1单抗。 ...

复宏汉霖(02696)再涨超5%，截至发稿，涨6.02%，报68.7港元，成交额3425.31万港元。 消息面上，11月12日，CDE官网公示，复宏汉霖PD-1抗体药物斯鲁利单抗注射液(H药)拟纳入突破性疗 法，用于联合化疗新辅助/辅助治疗胃癌，这是其首次拟获此认定。据悉，H药是全球首个获批一线治疗 小细胞肺癌的抗PD-1单抗。 值得注意的是，11月6日与11月10日，博裕资本(Boyu Capital Investment Management Limited)分别买入复 宏汉霖262,500股及80,000股H股，两次增持后其H股好仓比例由5.84%跃升至7%。据悉，今年6月18日， 博裕资本就已斥资2126.73万港元增持，将好仓比例从4.89%提升至5.15%，跨越5%的举牌线。 ...